menu
    • menu

    Company profile for Ellipses Pharma

    NEW Drugs in Dev: 5
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Support...
    Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ellipses Pharmaunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    10 Stratton Street W1J 8LG London
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ellipses.life/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ellipses-pharma/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ellipses Licenses First-In-Class B7H3 ADC From China
    Ellipses Licenses First-In-Class B7H3 ADC From China

    22 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260122512461/en/Ellipses-In-Licenses-First-in-Class-B7H3-Antibody-Drug-Conjugate-From-China

    BUSINESSWIRE
    22 Jan 2026
    Share Share
    Ellipses's 1st-In-Class Immuno-Oncology Checkpoint Inhibitor
    Ellipses's 1st-In-Class Immuno-Oncology Checkpoint Inhibitor

    11 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250211036005/en

    BUSINESSWIRE
    11 Feb 2025
    Share Share
    Ellipses Launches Clinical Trial Programme in Middle East
    Ellipses Launches Clinical Trial Programme in Middle East

    23 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241222005554/en

    BUSINESSWIRE
    23 Dec 2024
    Share Share
    Ellipses' RET Inhibitor EP0031/A400 Clears For Phase 2
    Ellipses' RET Inhibitor EP0031/A400 Clears For Phase 2

    01 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ellipses-next-generation-selective-ret-inhibitor-ep0031a400-cleared-to-start-phase-2-302132023.html

    PR NEWSWIRE
    01 May 2024
    Share Share
    Ellipses Pharma Announces Intent to Accelerate Clinical Programme
    Ellipses Pharma Announces Intent to Accelerate Clinical Programme

    05 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230605005430/en

    BUSINESSWIRE
    05 Jun 2023
    Share Share
    Ellipses Pharma: Expansion of Scientific Affairs Group
    Ellipses Pharma: Expansion of Scientific Affairs Group

    30 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230328005018/en

    BUSINESSWIRE
    30 Mar 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search